Tight Glycemic Control by Artificial Pancreas (KMS)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2008 by Kochi University.
Recruitment status was  Recruiting
Oita University
University of Tokushima
Information provided by:
Kochi University
ClinicalTrials.gov Identifier:
First received: August 12, 2008
Last updated: August 15, 2008
Last verified: August 2008
Hyperglycaemia has been repeatedly associated with risk of mortality and morbidity in the intensive care unit (ICU). The evidence currently available is in favour of a 'normal ≤ 6.1 mmol/l' level for blood glucose control in ICUs according to two large randomized control trials of Van den Berghe G and is not supportive of J. Miles's viewpoint in this debate. In this study, the investigators would like to evaluate that the target of blood glucose level, whether is a normal level (80-110 mg/dL) or another level (140-160 mg/dL), should be set for the reduction of perioperative mortality and complications.

Condition Intervention
Pancreatic Disease
Cardiovascular Diseases
Device: Artificial pancreas

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Benefit of Tight Glycemic Control in Surgical Patients: Prospective Randomized Clinical Trial

Resource links provided by NLM:

Further study details as provided by Kochi University:

Primary Outcome Measures:
  • The incidence of hypoglycemia [ Time Frame: during hospitalization ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • The incidence of postoperative infectious complications and calculate the total costs during hospitalization [ Time Frame: during hospitalization ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 400
Study Start Date: August 2008
Estimated Study Completion Date: August 2012
Estimated Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Perioperative blood glucose was controlled within the normal levels (80-110 mg/dL) by artificial pancreas.
Device: Artificial pancreas
Artificial endocrine pancreas (NIKKISO Company)
Other Name: artificial endocrine pancreas (NIKKISO Company)
Active Comparator: 2
Perioperative blood glucose concentration was controlled within the range from 140 to 160 mg/dL by artificial pancreas.
Device: Artificial pancreas
Artificial endocrine pancreas (NIKKISO Company)
Other Name: artificial endocrine pancreas (NIKKISO Company)

Detailed Description:
Our previous prospective randomized clinical trial suggested that the postoperative morbidities were reduced by tight glycemic control of a normal level for blood glucose using artificial pancreas. However, the most feared one is hypoglycaemia, which, when severe and prolonged, may cause convulsions, coma and brain damage, as well as cardiac arrhythmias. Recently, Ven den Berghe G report that the development of accurate, continuous blood glucose monitoring devices, and preferably closed-loop systems for computer-assisted blood glucose control in the ICU, will help to avoid hypoglycaemia. In our study, no hypoglycemia showed in more than 100 patients who performed perioperative tight glycemic control by artificial pancreas.

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Patients who were suffering from liver, pancreas or cardio-vascular diseases, were informed of the purpose and details of the study, and written consent was obtained from them prior to enrolment.

Exclusion Criteria:

  • Patient exclusion criteria included a body weight loss greater than 10% during the six months prior to surgery
  • The presence of distant metastases, or seriously impaired function of vital organs due to respiratory, renal or heart disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00735228

Contact: Takehiro Okabayashi, MD, PhD +81-88-880-2370 tokabaya@kochi-u.ac.jp
Contact: Kazuhiro Hanazaki, Prof +81-88-880-2370 im31@kochi-u.ac.jp

Kochi Medical School Recruiting
Nankoku, Japan, 783-8505
Contact: Takehiro Okabayashi, MD, PhD    +81-88-880-2370    tokabaya@kochi-u.ac.jp   
Contact: Kazuhiro Hanazaki, Prof    +81-88-880-2370    im31@kochi-u.ac.jp   
Principal Investigator: Takehiro Okabayashi, MD, PhD         
Sponsors and Collaborators
Kochi University
Oita University
University of Tokushima
Study Director: Takehiro Okabayashi, MD, PhD Kochi Medical School
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Kochi Medical School, Kochi University
ClinicalTrials.gov Identifier: NCT00735228     History of Changes
Other Study ID Numbers: GCAP0802  Kochi Medical School 
Study First Received: August 12, 2008
Last Updated: August 15, 2008
Health Authority: Japan: Ministry of Education, Culture, Sports, Science and Technology

Keywords provided by Kochi University:
artificial pancreas
tight glycemic control

Additional relevant MeSH terms:
Cardiovascular Diseases
Pancreatic Diseases
Digestive System Diseases
Gastrointestinal Agents

ClinicalTrials.gov processed this record on May 22, 2016